Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS: We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS: During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS: Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016-002299-28.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared with placebo, OM reduced incidence of the primary outcome over 22 months of follow-up (37.0% vs 39.1%; HR, 0.92 [95% CI 0.85-0.99]).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [72]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationRegularization Paths for Cox's Proportional Hazards Model via Coordinate Descent
Simon, N., Friedman, J., Hastie, T., & Tibshirani, R. (2011) · Journal of Statistical Software · doi:10.18637/jss.v039.i05 · Cited by 2,499
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033502 · Cited by 750
Self-citationCardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Malik, F. I., Hartman, J. J., Elias, K. A., Morgan, B. P., Rodriguez, H., Brejc, K., Anderson, R. L., Sueoka, S. H., Lee, K. H., Finer, J. T., et al. (2011) · Science · doi:10.1126/science.1200113 · Cited by 584
Self-citationRepeated assessment of results in clinical trials of cancer treatment
Haybittle, J. L. (1971) · The British Journal of Radiology · doi:10.1259/0007-1285-44-526-793 · Cited by 517
Kramer, D. G., Trikalinos, T. A., Kent, D. M., Antonopoulos, G. V., Konstam, M. A., & Udelson, J. E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.011 · Cited by 492
Cited by
Items 601–700 of 709
Pharmacological Management of Heart Failure: A Review of Recent Progress
Pan, Q., Li, X., Chen, W., & Zhuang, W. (2026) · Cardiology Discovery · doi:10.1097/cd9.0000000000000187
Ono, R., Chimura, M., Docherty, K. F., Jhund, P. S., Yang, M., Henderson, A. D., Tolomeo, P., Metra, M., Liu, G., Divanji, P., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag003
Self-citationHeart Failure Treatment—The Last Pieces of the Puzzle
Ioniţă, O., & Dorobantu, L. F. (2025) · Springer eBooks · doi:10.1007/978-3-031-96562-3_18
Azam, M. H., Wahab, M. A., Shahzad, M., Iqbal, F., Danish, S., Naeem, S., & Bhatti, K. I. (2025) · Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University · doi:10.48036/apims.v21i1.1208
The Current Evolutions in the Pharmacotherapeutic Management of Heart Failure
Jothieswari, D., Dwarakesh, B., Deepak, A., V, & Dharshini Priya, A. (2022) · World Journal of Current Medical and Pharmaceutical Research · doi:10.37022/wjcmpr.v4i2.211
New Saviour for An Old Problem: Omecamtiv Mecarbil for Systolic Heart Failure
Prabhu, M. M., Palaian, S., & Kumar, P. (2021) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2021.110
Chaparro, S. V., & Rivera-Rodríguez, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-54441-6_192
Chaparro, S. V., & Rivera-Rodríguez, M. (2021) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_192-1
Pharmacological Treatment in Patients with Advanced Heart Failure: Recommendations and Challenges
Scussel, F. (2022) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20220021
Research on the source of nitric acid and its detection and medical application
Liu, S., Gong, X., Zhu, T., Yan, S., Qin, M., Chen, X., & Chen, H. (2025) · Scientia Sinica Chimica · doi:10.1360/ssc-2024-0293
Trimetazidine in Heart Failure: From Metabolic Modulation to Clinical Outcomes—A Narrative Review
Pradhan, A. K., Prajapathi, S., Mahajan, K., Batta, A., & Perrone, M. A. (2026) · Pharmaceuticals · doi:10.3390/ph19101663
Cardiologia – Teoria e Prática Ed. XXII
Guilherme Barroso L. de Freitas, C. C. D. A. (2025) · Editora Pasteur eBooks · doi:10.59290/978-65-6029-266-6
EDUCAÇÃO EM SAÚDE PARA O CONTROLE POPULACIONAL DE CÃES E GATOS EM SÃO LUÍS - MA
de Oliveira, F. M., Ferreira, J. M. T., Abreu, W. M., Vieira, T. A., & Lacerda, L. D. M. (2023) · doi:10.22533/at.ed.6942309012
PIOMETRA EM GATAS : RELATO DE CASO
Santos, A. R., Ribeiro, I. E., Pereira, T. M. B., da Silva, T. H. R., & Rodrigues, D. D. F. (2023) · doi:10.22533/at.ed.69423090110
MUTIRÃO DE CASTRAÇÃO DE PEQUENOS ANIMAIS – REVISÃO BIBLIOGRÁFICA
Rohloff, C. D. M. G., de Almeida, G. T., dos Santos, I. F., da Silva, T. D. S., & Rodrigues, D. D. F. (2023) · doi:10.22533/at.ed.6942309016
PERFIL DIURÉTICO DA FUROSEMIDA EM RATOS SUBMETIDOS À INSUFICIENCIA CARDÍACA
Moura, J. C., de Lima, B. D. S. F., Oliveira, E. C. N., Souza, G. A. B. C. E., Andrade, L. P., de Brito, E. R., Barros, D. V., de Carvalho, M. B. B., Penha, E. C. D. S., Salgado, N. M. D. C., et al. (2023) · doi:10.22533/at.ed.6942309017
Rosalem, M., de Assis, J. V., Bento, S. A. A., Faria, A. L. B. D. S., Toledo, H. R. P., Damião, I. L., da Silva, V. N. F., Finotti, A. R., Quim, C. E. D. P., & Zero, R. C. (2023) · doi:10.22533/at.ed.6942309014
Almeida, C. H. C., Santana, E. M., Accioly, G. D. S. G., Almeida, A. C. S., & Tamashiro, G. D. (2023) · doi:10.22533/at.ed.6942309011
HEMANGIOSSARCOMA CUTÂNEO EM GATOS: RELATO DE CASO
Gonçalves, T. R. O., Galan, G. P., Martins, V. Z., & Rodrigues, D. D. F. (2023) · doi:10.22533/at.ed.6942309015
The role of cardiac myosin activators in dilated cardiomyopathy pharmacotherapy
Garcia, E. S., Taylor, M. R. G., Mestroni, L., & Lombardi, R. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2682840
Durango, L. V., Echeverri, L. M. G., Buitrago-Bach, R., & Gómez, J. R. M. (2025) · Salud Uninorte · doi:10.14482/sun.41.02.484.070
(2021) · Journal of JCS Cardiologists · doi:10.1253/jjcsc.30.0_78
Geographical and Ethnic Heterogeneity in Genetic Dilated Cardiomyopathies
Peppo, M. D., Biancofiore, G., Crudo, A. F., Gulino, G., Costabile, E., Margaglione, A., D'Ambrosio, M., Correale, M., Brunetti, N. D., Santacroce, R., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146342
Girault-Sotias, P.-E. (2022) · theses.fr (ABES) · doi:10.70675/5f642fbbz3ee5z4109zbb61z1bcb96fa1556
Chuzi, S. E., & Yancy, C. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00034-7
Herzinsuffizienz: Diagnostik und Therapie gemäß der ESC Leitlinie 2021
Herting, J., Fischer, T. H., & Maack, C. (2022) · Die Kardiologie · doi:10.1007/s12181-022-00569-x
Herzinsuffizienz: Diagnostik und Therapie gemäß der ESC Leitlinie 2021
Herting, J., Fischer, T. H., & Maack, C. (2022) · Zeitschrift für Herz- Thorax- und Gefäßchirurgie · doi:10.1007/s00398-022-00544-4
Current treatment approaches in the management of the heart failure
Başgöz, B. B., Öztürk, C., Varhan, C., & Solmaz, İ. (2024) · Intercontinental Journal of Internal Medicine · doi:10.51271/icjim-0031
EMERGING SMALL-MOLECULE THERAPEUTICS FOR DILATED CARDIOMYOPATHY
Wei, Z., & Aubele, D. L. (2022) · Medicinal chemistry reviews · doi:10.1021/mc-2022-vol57.ch06
Muff, V. (2023) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/epub.54995
Denfeld, Q. E., & Butler, J. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.11.013
Troponin in Heart Failure: Innocent Bystander or Harbinger of Risk?
Shah, A., & Rao, V. N. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.04.004
Die intrahospitale dynamische Modulation der systolischen Ejektionszeit bei akuter Herzinsuffizienz
Simon, I. (2024) · Online Publication Service of Würzburg University (Würzburg University) · doi:10.25972/opus-37560
Unveiling Heart Failure: Gender-Specific Insights and Innovations in Women's Cardiac Health
Bhati, A., Sharma, N., Shah, K., Bhatia, D., & Dewangan, H. K. (2026) · Current Pharmaceutical Design · doi:10.2174/0113816128399624251015180709
Bhatty, A. N. (2026) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Ishizaka, M., Hsu, H., Miyagawa, Y., & TAKEMURA, N. (2024) · Open Veterinary Journal · doi:10.5455/ovj.2024.v14.i12.42
(2025) · JACC Heart Failure · doi:10.1016/s2213-1779(25)00463-9
Ruppert, M., Claggett, B. L., Merkely, B., McMurray, J. J. V., Felker, G. M., Metra, M., Díaz, R., Malik, F. I., Divanji, P., Kupfer, S., et al. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103473
Self-citationBragança, B. M. M. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/br07-4v73
Jarjour, M. (2022) · Papyrus : Institutional Repository (Université de Montréal) · doi:10.71781/26558
The paradigm to overcome in acute decompensated heart failure
González-Ruiz, F. J., Encarnación-Martínez, U., & Gaytán-García, C. J. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae069
SCHNETTLER, J. K. (2023) · Refubium (Universitätsbibliothek der Freien Universität Berlin) · doi:10.17169/refubium-36687
Zamudio, J. A. T. (2026) · Universidad de Córdoba Insitutional Repository (Universidad de Córdoba)
PIORA CLÍNICA NA INSUFICIÊNCIA CARDÍACA: IDENTIFICAÇÃO DE DESAFIOS E CONDUTAS TERAPÊUTICAS
Faria, T. M., Rodrigues, A. M. D. A. M., Leite, F. M., Araújo, D. C. L., Rocha, F. F. P. G., & Lima, M. M. D. M. (2026) · EPITAYA eBooks · doi:10.47879/ed.ep.20260415p462
Bánfi‐Bacsárdi, F. (2025) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.12353
Discovery and Care Innovation Amidst a Pandemic
Bhatt, A. S., & Vaduganathan, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2070
Okwah, M. N., Akinrele, O. R. A., Abah, M. A., Abimbola, M. O., Muhammed, R. O., & Nmecha, O. N. N. O. N. (2026) · International journal of research in medical and clinical science. · doi:10.70829/ijrmcs.v04.i01.030
Standardizing the standard: reporting health status in clinical trials
Arnold, S. V., Butler, J., & Spertus, J. A. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2117
Lindberg, F. (2024) · Open Archive (Karolinska Institutet)
Messner, M., & Zaruba, M. (2021) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Cardiomyocyte-Derived Cell-Free DNA in Hypertrophic CardiomyopathyPreprint
Kamna, D., Davis, B. A., Layman, C., Wiedrick, J., Avaylon, S., Wheeler, K., Jahan, I., Carbone, L., & Masri, A. (2026) · medRxiv · doi:10.64898/2026.10.12.26365358
Craciun, M.-L., Rada, M., Pah, A.-M., Crișan, S., Văcărescu, C., Surducan, D. A., Tudoran, C., Cotet, I.-G., & Avram, A. C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15228983
Mendonça, P. J. L. D. A., Torquato, G. M., Bambeko, I. M., Cavalcante, M. D. S., & Portela, L. C. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.ceg164.1123-3
Santhosh, S. (2026) · Journal of chemical health risks
Elnour, A. A., Sadeq, A. S., Ramadan, A., Alamoodi, A., Alkawarit, A., Alshammari, A. F., Khidir, I. Y., Alrashidi, N. E., Kouhgard, P., Alqahtani, M. M., et al. (2023) · Pharmacy Practice · doi:10.18549/pharmpract.2023.2.2824
Ališauskas, A. (2023) · Lithuanian University of Health Sciences
Maggioni, A. P. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.12.042
Isnard, R. (2021) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2021.01.001
Innovations in Heart Failure Wanted
Albert, N. M. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.07.002
Current pharmacological treatment of heart failure: What is new in the 2021 ESC guidelines?
Stańczyk, A., & Barlicki, N. (2021) · Heart Vessels and Transplantation · doi:10.24969/hvt.2021.274
Prospects of heart failure pharmacotherapy: the latest news about omecamtiv mecarbil
Kravchenko, I. G., Rudyk, I. S., & Medentseva, O. (2021) · Ukrainian Therapeutical Journal · doi:10.30978/utj2021-3-73
HFrEF: Neuer Myosin-Aktivator Omecamtiv Mercabil verbessert Prognose
Franke, K. (2021) · Aktuelle Kardiologie · doi:10.1055/a-1331-3216
PHARMACOLOGICAL PROFILE OF LOOP DIURETIC IN EXPERIMENTAL MODEL OF HEART FAILURE
Moura, J. C., Mendes, V. S., de Oliveira, G. G., Souza, G. A. B. C. E., de Lima, B. D. S. F., Salgado, N. M. D. C., Andrade, L. P., Silva, L. T. D. S., Lopes, I. T., Teixeira, E. T., et al. (2022) · International Journal of Health Science · doi:10.22533/at.ed.1592192208047
Massimo, V., & Carlo, P. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1017
Omecamtiv mecarbil does not impact exercise capacity of patients with HFrEF
Felker, G. M., & Giles, R. (2022) · doi:10.55788/29b50f64
Self-citationXu, B., Zhao, J., Li, Z., Yu, L., & Wang, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1752754/v1
Omecamtiv Mecarbil: Decisional Dilemmas and Regulatory Science – Opportunities for Improvement?
Hernandez, A. F. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.01.001
Emerging Pharmacologic Targets for Inotropic Support
Garland, H. (2023) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2023.06.042
Biegus, J., Ponikowski, P. P., & Maack, C. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780198891628.003.0049
Self-citationAdvanced heart failure: management
Tomasoni, D., Adamo, M., & Metra, M. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780198891628.003.0062
Self-citationHerrera-Leaño, N., Correa, J. E. B., Múñoz, Ó., Fernández-Ávila, D. G., & Peña, Á. A. G. (2024) · Revista Colombiana de Cardiología · doi:10.24875/rccar.22000008
Herrera-Leaño, N., Correa, J. E. B., Múñoz, Ó., Fernández-Ávila, D. G., & Peña, Á. A. G. (2024) · Revista Colombiana de Cardiología (English Edition) · doi:10.24875/rccare.m23000074
Gaggin, H. K., Greene, S. J., Zhou, M., Lautsch, D., Bash, L. D., Djatche, L. M., Song, Y., Signorovitch, J., Stevenson, A. S., Blaustein, R. O., et al. (2024) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2024.200278
Inotropes in Advanced Heart Failure: The Last Tool in the Box of Failures?
Haider, L., & Mewton, N. (2024) · Cardiology · doi:10.1159/000538994
Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and meta-analysis
Ibrahim, R. (2024) · International Journal of Cardiology and Cardiovascular Diseases · doi:10.46439/cardiology.4.028
NOVAS TERAPIAS NO MANEJO DA INSUFICIÊNCIA CARDÍACA COM FRAÇÃO DE EJEÇÃO REDUZIDA (ICFER)
Dantas, D. A., Moreira, G. F., da Cunha, R. L. N., AGNE, I. A., Gomes, D. R. M., Teixeira, Y. D. C. S., Maia, B. C. C., & Perina, K. C. B. (2025) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2025v7n5p282-297
Akkan, G., Kırış, T., Esin, F. K., & Karaca, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093226
Balarezo-García, M. G., Suárez-Páez, D. A., Moreano-Camalli, M. J., & Viteri-Paredes, R. J. (2025) · Sanitas. Revista arbitrada de ciencias de la salud. · doi:10.62574/g7pyr688
The Mechanism and Therapeutic Progress of Heart Failure after Myocardial Infarction
宋, 灵. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1572062
Farmacologia do tratamento da insuficiência cardíaca com fração de ejeção reduzida
Lamas, J. M. M. A. C. E., de Camargos, E. R. F. G., Salgado, C. L., & Pereira, F. F. A. A. (2025) · Editora Pasteur eBooks · doi:10.59290/0900125222
Step by Step to Precision Medicine in Cardiomyopathy Therapy
Kransdorf, E. P., & Kittleson, M. M. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.10.035
Omecamtiv Mecarbil – a new drug to improve quality of life in patients with heart failure?
Matos, B. F. D. S. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
VIII МЕЖДУНАРОДНЫЙ ОБРАЗОВАТЕЛЬНЫЙ ФОРУМ “РОССИЙСКИЕ ДНИ СЕРДЦА”. ДНЕВНИК ПРОЕКТА
Lyapina, I. N., Чичкова, Т. Ю., & Teplova, Y. E. (n.d.) · CyberLeninK (CyberLeninka)
Pharmacological and Non-Pharmacological Heart Failure Treatment with Reduced Systolic Function
Trbušić, M., & Radić, P. (2025) · University of Zagreb University Computing Centre (SRCE)
Fukuta, H., & Goto, T. (2026) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2026.101881
Pagidiboina, H. C., Thurikepally, L., Puchongmart, C., Thiravetyan, B., & Ramavath, S. (2026) · The Southwest Journal of Medicine · doi:10.12746/swjm.v14i58.1563
Small Molecules to Treat Cardiovascular Disease: Cardiac Myosin Inhibitors
Wilsbacher, L. D. (2026) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2026.0005
Sun, M., Li, Q., Chen, K., Ma, K., Fang, X., Wang, B., Ye, Z., Ren, Y., Khuzin, D., & Han, W. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70258
Motor Occupancy Drives Emergent Mechanical States in Cardiac Myosin EnsemblesPreprint
Azzam, O. Y. A., Chowdhury, M. A. H., Stevens, H. M., & Reinemann, D. N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.17.739215
Are We Setting Heart Failure Drug Development Up for Failure?
Sen, S., & Ahmad, T. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103282
MMP-9 Gene Ablation Preserves Ejection Fraction During “Single-Hit” Model of HFrEF
Akinterinwa, O. E., Singh, M., Zheng, Y., & Tyagi, S. C. (2026) · Biochemical Genetics · doi:10.1007/s10528-026-11438-7
Cardiac Myosin-Binding Protein C in Cardiovascular Disease
Asuzu, C., Catanzaro, J. N., Fishkin, T., Makaryus, A. N., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001436
Effect of Omecamtiv Mecarbil According to PREDICT-HF Risk Score
Chimura, M., McDowell, K., Jhund, P. S., Docherty, K. F., Yang, M., Metra, M., Felker, G. M., Solomon, S. D., Teerlink, J. R., & McMurray, J. J. V. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103302
Self-citation
Metadata
- Authors
- Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sørensen, T., Böhm, M., Bonderman, D., Cleland, J. G. F., Corbalan, R., Crespo-Leiro, M. G., Dahlström, U., Echeverria, L. E., Fang, J. C., Filippatos, G., Fonseca, C., Goncalvesova, E., Goudev, A. R., Howlett, J. G., Lanfear, D. E., Li, J., Lund, M., Macdonald, P., Mareev, V., Momomura, S.-I., O’Meara, E., Parkhomenko, A., Ponikowski, P., Ramires, F. J. A., Serpytis, P., Sliwa, K., Spinar, J., Suter, T. M., Tomcsanyi, J., Vandekerckhove, H., Vinereanu, D., Voors, A. A., Yilmaz, M. B., Zannad, F., Sharpsten, L., Legg, J. C., Varin, C., Honarpour, N., Abbasi, S. A., Malik, F. I., & Kurtz, C. E.
- Affiliations
- San Francisco VA Medical Center (US)
- From the Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, San Francisco (J.R.T.), Amgen, Thousand Oaks (L.S., J.C.L., N.H., S.A.A., C.E.K.), and Cytokinetics, South San Francisco (F.I.M.) — all in California; Estudios Clínicos Latino América, Rosario, Argentina (R.D.); the Division of Cardiology, Duke University School of Medicine and Duke Clinical Research Institute, Durham (G.M.F.), and the University of North...
- Brigham and Women's Hospital (US)
- University of North Carolina at Chapel Hill (US)
- University of Minnesota (US)
- Linköping University (SE)
- University of Bern (CH)
- ORCID
- Teerlink, John R.
- Felker, G. Michael
- McMurray, John J.V.
- Metra, Marco
- Solomon, Scott D.
- Anand, Inder
- Böhm, Michael
- Bonderman, Diana
- Cleland, John G.F.
- Dahlström, Ulf
- Fang, James C.
- Filippatos, Gerasimos
- Fonseca, Cândida
- Goudev, Assen R.
- Howlett, Jonathan G.
- Lanfear, David E.
- Li, Jing
- Lund, Mayanna
- Macdonald, Peter
- Momomura, Shin-ichi
- O’Meara, Eileen
- Parkhomenko, Alexander
- Ponikowski, Piotr
- Sliwa, Karen
- Voors, Adriaan A.
- Zannad, Faiez
- Abbasi, Siddique A.
- Malik, Fady I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-01-14
- Volume
- 384
- Issue
- 2
- Pages
- 105-116
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3098430919
- Cited by
- 656
- References
- 26
- Citations by year
- 2026: 51 · 2025: 84 · 2024: 76 · 2023: 150 · 2022: 130 · 2021: 148
- FWCI
- 68.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Archive of Doctoral Theses and Digital Collections (University of Calabria) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- RUC (Universidade Da Coruña) (submittedVersion)
- Funders
- Amgen
- Cytokinetics Inc.
- Servier
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- omecamtiv mecarbil, cardiac myosin activator, heart failure with reduced ejection fraction, cardiovascular outcomes, heart failure hospitalization, cardiovascular mortality, N-terminal pro-brain natriuretic peptide, cardiac troponin I, symptom burden, pharmacokinetic-guided dosing, ventricular arrhythmias
- MeSH terms
- Aged, Aged, 80 and over, Cardiotonic Agents, Cardiovascular Diseases, Female, Humans, Male, Middle Aged, Myocardial Contraction, Stroke Volume, Urea, Cardiac Myosins, Heart Failure, Systolic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.